| Literature DB >> 30666137 |
Aghil Bahramian1,2, Saeed Khoshnood3,4, Aref Shariati5, Farahnoosh Doustdar2, Alireza Salimi Chirani2, Mohsen Heidary5,6.
Abstract
INTRODUCTION: Pseudomonas aeruginosa is the most common opportunistic pathogen associated with a broad range of infections, including cystic fibrosis, ocular, otitis media, and burn infections. The aim of this study was to show the frequency of the pilS2 gene, and its association with P. aeruginosa plasmid pKLC102 and PAPI-1 pathogenicity island among P. aeruginosa strains.Entities:
Keywords: PAPI-1; Pseudomonas aeruginosa; cystic fibrosis; pKLC102; pilS2
Year: 2019 PMID: 30666137 PMCID: PMC6333160 DOI: 10.2147/IDR.S188527
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Primer sequence used in the genetic characterization of Pseudomonas aeruginosa clinical strains
| Gene/genomic islands | Forward primer sequence (5′–3′) | Reverse primer sequence (5′–3′) | Size of PCR product (bp) | Tm (°C) |
|---|---|---|---|---|
| GCGGTTTCGTTTCCATCGAG | GGTCACTTCTCCGGTGATCG | 428 | 60 | |
| pKLC102 | ||||
| CGGACCACTAGATAGCCAGG | GGACGCCATTGAGTATGCGC | 255 | 61 | |
| GGGTCCGCAAAACTTTCCGC | GCTTGAGGTTGGGCCAATCG | 272 | 61 | |
| GGATATCTACGTACCCCGGC | CTTTTTACCCGCAGTGGCGG | 337 | 61 | |
| PAPI-1 | ||||
| 976F/PAPI-1R | GCCTGACGGTGTCCTGTTAT | GCTGCCTCTCCTACGAACA | 2,600 | 58 |
| 4542F/intF | GTGGTGATGACCTCCAACCT | AGCTACATCGAGGCCGACTA | 1,600 | 58 |
| SojR/4541F | CGAGCACAGAAATGTCCTGA | GACAAGACCAGCCACAACCT | 1,600 | 58 |
| intF/sojR | AGCTACATCGAGGCCGACTA | CGAGCACAGAAATGTCCTGA | 1,600 | 58 |
Antibiotic resistance patterns in Pseudomonas aeruginosa isolates
| Antibiotic | Cystic fibrosis N (%) | Burn wound infections N (%) | Otitis media N (%) | Ocular infections N (%) | Total N (%) |
|---|---|---|---|---|---|
| Cotrimoxazole | 27 (75) | 17 (85) | 22 (84) | 22 (73) | 88 (79) |
| Cefoperazone-sulbactam | 17 (47) | 9 (45) | 12 (46) | 14 (46) | 52 (46) |
| Amikacin | 24 (66) | 16 (80) | 19 (73) | 25 (83) | 84 (75) |
| Piperacillin-tazobactam | 28 (77) | 16 (80) | 20 (76) | 23 (76) | 87 (77) |
| Piperacillin | 32 (88) | 14 (70) | 21 (80) | 24 (80) | 91 (79) |
| Cefepime | 31 (86) | 17 (85) | 22 (84) | 29 (96) | 99 (88) |
| Tobramycin | 23 (63) | 10 (50) | 11 (42) | 17 (56) | 61 (54) |
| Meropenem | 33 (91) | 17 (85) | 22 (84) | 26 (86) | 98 (87) |
| Imipenem | 33 (91) | 17 (85) | 22 (84) | 26 (86) | 98 (87) |
| Gentamicin | 34 (94) | 16 (80) | 23 (88) | 26 (86) | 99 (88) |
| Ceftazidime | 22 (61) | 14 (70) | 22 (84) | 24 (80) | 82 (73) |
| Colistin | 0 (0) | 0 (0) | 2 (7) | 3 (10) | 5 (4) |
| Ciprofloxacin | 33 (91) | 18 (90) | 21 (80) | 27 (90) | 99 (88) |
| Aztreonam | 30 (83) | 16 (80) | 20 (76) | 27 (90) | 93 (83) |
Figure 1Detection of pils2 gene (428 bp) in Pseudomonas aeruginosa isolates.
Notes: 1–3 and 5 positive samples, 4 and 6 negative samples; molecular pattern: 100 bp.
Abbreviations: N, negative control; P, positive control.
Figure 2Detection of CP44 gene (272 bp) in Pseudomonas aeruginosa isolates.
Note: Molecular pattern: 100 bp.
Abbreviations: N, negative control; P, positive control.
Figure 3Detection of CP10 gene (255 bp) in Pseudomonas aeruginosa isolates.
Note: Molecular pattern: 100 bp.
Abbreviations: N, negative control; P, positive control.
Frequency of the specific genes CP10, CP44, and CP97 of pKLC102
| Genotype | CF | Eye | Ear | Burn | Total (%) |
|---|---|---|---|---|---|
|
| |||||
| cp10− cp44− cp97− | 18 | 3 | 11 | 1 | 33 (29.4) |
| cp10+ cp44− cp97− | 6 | 9 | 2 | 4 | 21 (18.7) |
| cp10− cp44+ cp97− | 9 | 0 | 0 | 2 | 11 (9.8) |
| cp10− cp44− cp97+ | 0 | 0 | 0 | 0 | 0 |
| cp10+ cp44+ cp97− | 3 | 16 | 0 | 9 | 28 (25) |
| cp10+ cp44− cp97+ | 0 | 0 | 0 | 1 | 1 (0.9) |
| cp10− cp44+ cp97+ | 0 | 1 | 12 | 0 | 13 (11.6) |
| cp10+ cp44+ cp97+ | 0 | 1 | 1 | 3 | 5 (4.4) |
Abbreviation: CF, Cystic fibrosis.
The association of pilS2 with pKLC102, chromosomal PAPI-1, and plasmid PAPI-1
| Genotype | Cystic fibrosis N (%) | Eye N (%) | Ear N (%) | Burn N (%) | Total N (%) |
|---|---|---|---|---|---|
|
| |||||
| pKLC102− chromosomal PAPI1− plasmid PAPI1− pilS2− | 6 (16.6) | 0 | 3 (11.5) | 0 | 9 (8) |
| pKLC102+ chromosomal PAPI1− plasmid PAPI1− pilS2− | 0 | 0 | 0 | 0 | 0 |
| pKLC102− chromosomal PAPI1+ plasmid PAPI1− pilS2− | 3 (8.3) | 0 | 0 | 0 | 3 (2.6) |
| pKLC102− chromosomal PAPI1− plasmid PAPI1+ pilS2− | 0 | 0 | 0 | 0 | 0 |
| pKLC102− chromosomal PAPI1− plasmid PAPI1− pilS2+ | 3 (8.3) | 3 (10) | 4 (15.3) | 0 | 10 (8.9) |
| pKLC102+ chromosomal PAPI1+ plasmid PAPI1− pilS2− | 0 | 0 | 0 | 0 | 0 |
| pKLC102+ chromosomal PAPI1− plasmid PAPI1+ pilS2− | 3 (8.3) | 0 | 0 | 0 | 3 (2.6) |
| pKLC102+ chromosomal PAPI1− plasmid PAPI1− pilS2+ | 0 | 0 | 0 | 0 | 0 |
| pKLC102− chromosomal PAPI1+ plasmid PAPI1+ pilS2− | 0 | 0 | 0 | 0 | 0 |
| pKLC102− chromosomal PAPI1+ plasmid PAPI1− pilS2+ | 6 (16.6) | 0 | 4 (15.3) | 1 (5) | 11 (9.8) |
| pKLC102− chromosomal PAPI1− plasmid PAPI1+ pilS2+ | 0 | 0 | 0 | 0 | 0 |
| pKLC102+ chromosomal PAPI1+ plasmid PAPI1+ pilS2− | 1 (2.7) | 0 | 0 | 0 | 1 (0.8) |
| pKLC102+ chromosomal PAPI1+ plasmid PAPI1− pilS2+ | 0 | 0 | 0 | 0 | 0 |
| pKLC102+ chromosomal PAPI1− plasmid PAPI1+ pilS2+ | 11 (30.5) | 17 (56.6) | 6 (23) | 5 (25) | 39 (38.8) |
| pKLC102− chromosomal PAPI1+ plasmid PAPI1+ pilS2+ | 0 | 0 | 0 | 0 | 0 |
| pKLC102+ chromosomal PAPI1+ plasmid PAPI1+ pilS2+ | 3 (8.3) | 10 (33.3) | 9 (34.6) | 14 (70) | 36 (32) |
The association of pKLC102 with chromosomal PAPI-1 and plasmid PAPI-1
| Genotype | Cystic fibrosis N (%) | Eye N (%) | Ear N (%) | Burn N (%) | Total N (%) |
|---|---|---|---|---|---|
|
| |||||
| pKLC102− chromosomal PAPI1− plasmid PAPI1− | 9 (25) | 3 (10) | 7 (26.9) | 0 | 19 (16.9) |
| pKLC102+ chromosomal PAPI1− plasmid PAPI1− | 0 | 0 | 0 | 0 | 0 |
| pKLC102− chromosomal PAPI1+ plasmid PAPI1− | 9 (25) | 0 | 4 (15.3) | 1 (5) | 14 (12.5) |
| pKLC102− chromosomal PAPI1− plasmid PAPI1+ | 0 | 0 | 0 | 0 | 0 |
| pKLC102+ chromosomal PAPI1+ plasmid PAPI1− | 0 | 0 | 0 | 0 | 0 |
| pKLC102+ chromosomal PAPI1− plasmid PAPI1+ | 14 (38.8) | 17 (56.6) | 6 (23) | 5 (25) | 42 (37.5) |
| pKLC102− chromosomal PAPI1+ plasmid PAPI1+ | 0 | 0 | 0 | 0 | 0 |
| pKLC102+ chromosomal PAPI1+ plasmid PAPI1+ | 4 (11.1) | 10 (33.3) | 9 (34.6) | 14 (70) | 37 (33) |